Thursday, August 11, 2022


Biotechnology News Magazine


Vicebio Launched by medicxi to Advance the Molecular Clamp Technology & Develop Next Generation RSV Vaccine

The Vicebio team has extensive experience in the research & development of innovative vaccines and has launched several commercially successful products using novel platform technologies.

Vaccizone Selects Exothera for process development & GMP Manufacturing of its SARS‑CoV‑2 Vaccine Based on Proprietary ASC Technology

Vaccizone selected Exothera to industrialize its COVID-19 vaccine production process in the scale-X™ technology (from Univercells Technology) and to manufacture clinical material for toxicological studies and European Phase I clinical trials.

Novavax Reports Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

Novavax advises the Swissmedic decision was based on the totality of preclinical, manufacturing and clinical trial data submitted for review.

CEPI Partners with Japan’s NEC Group

CEPI will provide seed funding of up to US$4.8m to NEC OncoImmunity AS (NOI)

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

Vaxcyte expects to announce topline safety, tolerability and immunogenicity results from both the Ph

Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)

Novavax President and Chief Executive Officer Stanley C. Erck said, "We are continuing to see spikes in COVID-19 across Europe and recognize the need to improve vaccination rates, particularly in the pediatric population."